# Long Term Safety Assessment of SER120 in Patients With Nocturia

> **NCT00981682** · PHASE3 · COMPLETED · sponsor: **Serenity Pharmaceuticals, Inc.** · enrollment: 376 (actual)

## Conditions studied

- Nocturia

## Interventions

- **DRUG:** SER120

## Key facts

- **NCT ID:** NCT00981682
- **Lead sponsor:** Serenity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-06
- **Final completion:** 2011-08
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00981682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00981682, "Long Term Safety Assessment of SER120 in Patients With Nocturia". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00981682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*